{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"BeyondSpring, Inc."},"Symbol":{"label":"Symbol","value":"BYSI"},"Address":{"label":"Address","value":"28 LIBERTY STREET,39TH FLOOR, NEW YORK, New York, 10005, United States"},"Phone":{"label":"Phone","value":"+1 646 305-6387"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"BeyondSpring Inc is engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. The Company has created Plinabulin which is marine derived small-molecule with a number of distinct biological activities that may provide multiple therapeutic opportunities. Plinabulin has increased the survival of neutrophils, a type of white blood cell important in the prevention of bacterial infections. The Company has a scalable business model integrating clinical resources in the United States and China."},"CompanyUrl":{"label":"Company Url","value":"https://www.beyondspringpharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"June Lu","title":"Chief Scientific Officer"},{"name":"Lan Huang","title":"Chairman & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}